MDPI AG
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Cardiovascular (CV) disease, chronic kidney disease, obesity, and diabetes mellitus have reached epidemic proportions over the past few decades. Accumulating evidence highlights the strong interconnection between these conditions, leading to the definition of a broader disease entity known as cardio-renal-metabolic (CRM) syndrome. This newly recognized clinical entity presents important challenges in identifying the optimal treatment strategy within a holistic, patient-centered framework. In line...
Preuzmite dokument
2025
Paschalis Karakasis
,
Efstratios Karagiannidis
,
Antonios P. Antoniadis
,
Nikolaos Fragakis
,
Athina Nasoufidou
,
Aleksandra Klisic
,
Konstantinos Grigoriou
,
Djordje S. Popovic
,
Panagiotis Stachteas
,
Dimitrios Patoulias
,
Barbara Fyntanidou
... Pogledajte sve
MDPI AG
Role of Interleukins in Type 1 and Type 2 Diabetes
Background: Despite distinct etiologies, type 1 diabetes (T1D) and type 2 diabetes (T2D) share chronic inflammation as a core feature. Interleukins, key immune mediators, play important yet still not fully understood roles in the development and complications of both conditions. Objective: This narrative review aims to provide a comprehensive and critical synthesis of current evidence on the role of key interleukins in T1D and T2D, highlighting their immunological functions, genetic associations,...
Preuzmite dokument
2025
Filiz Mercantepe
,
Sana Rafaqat
,
Saira Rafaqat
,
Aleksandra Klisic
,
Roha Asif
,
Ammara Khalid
,
Tolga Mercantepe
MDPI AG
The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
Background/Objectives: A significant breakthrough in non-small-cell lung cancer (NSCLC) treatment has occurred with the introduction of targeted therapies and immunotherapy. However, not all patients treated with these therapies would respond to treatment, and patients who respond to treatment would acquire resistance at some time point. This is why we need new biomarkers that can predict response to therapy. The aim of this study was to investigate whether soluble programmed cell death-ligand 1...
Preuzmite dokument
2025
Ivan Soldatović
,
Damir Radončić
,
Biljana Šeha
,
Dragana Jovanović
,
Milan Savić
,
Natalija Samardžić
,
Aleksandra Klisic
,
Jelena Kotur Stevuljević
,
Milija Gajić
,
Marina Roksandić Milenković
,
Nikola Čolić
,
Katarina Lukić
,
Vesna Ceriman Krstic
... Pogledajte sve
